This inventor holds 7 USPTO granted patents, plus 1 CIPO patent. Top assignees: Ono Pharmaceutical Co., Ltd., Ono Pharmaceuticals Co., Ltd.. Active years: 1992-1999.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1992-1999
Title: The Innovative Contributions of Takahiko Nakae
Introduction
Takahiko Nakae is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work primarily focuses on compounds that exhibit therapeutic effects, particularly in the area of inflammatory responses.
Latest Patents
Among his latest patents, Nakae has developed phenylalkan(en)oic acids, which possess antagonistic activity on leukotriene B.sub.4. This discovery has potential implications for treating various inflammatory conditions. Additionally, he has worked on sulfonamide derivatives that demonstrate an inhibitory effect on elastase, further showcasing his innovative approach to drug development.
Career Highlights
Nakae has been associated with notable companies such as Ono Pharmaceutical Co., Ltd. and Ono Pharmaceuticals Co., Ltd. His work in these organizations has allowed him to contribute to the advancement of pharmaceutical sciences and the development of new therapeutic agents.
Collaborations
Throughout his career, Nakae has collaborated with esteemed colleagues, including Mitoshi Konno and Nobuyuki Hamanaka. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Takahiko Nakae's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic agents that may improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile